Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study

Guerzoni, Simona; Baraldi, Carlo; Brovia, Daria; Michela, Cainazzo Maria; Flavia, Lo Castro; Pani, Luca

doi:10.1007/s13760-023-02190-5

Cited by 3 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fourteen studies were excluded either because they were based on the same cohort as an included study or because they did not provide measures of the association of interest. We included 38 studies [ 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ] in this review, which are summarized in Tables S1–S3 . The PRISMA flow diagram of the literature search process is displayed in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…We found three studies [ 70 , 71 , 72 ] specifically designed to determine if specific demographic factors predict response to CGRP(-R) mAbs. Cetta et al showed that similar reductions in monthly headache days (MHD) were seen in patients under and over the age of 65 [ 71 ].…”

Section: Resultsmentioning

confidence: 99%

“…Cetta et al showed that similar reductions in monthly headache days (MHD) were seen in patients under and over the age of 65 [ 71 ]. Guerzoni et al showed no difference in mean MHD reduction between patients pre- and post-menopause [ 72 ]. In the ESTEEMen study by Ornello et al, a pooled patient-level analysis of 1410 migraine patients, response to erenumab did not differ between male and female patients [ 70 ].…”

Section: Resultsmentioning

confidence: 99%

“…A negative family history of migraine was associated with a decreased likelihood of response to CGRP(-R) mAbs (OR: 0.4, 95% CI: 0.16-0.97) in one study [42]. We found three studies [70][71][72] specifically designed to determine if specific demographic factors predict response to CGRP(-R) mAbs. Cetta et al showed that similar reductions in monthly headache days (MHD) were seen in patients under and over the age of 65 [71].…”

Section: Demographic Characteristicsmentioning

confidence: 97%

See 3 more Smart Citations

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response

et al. 2023

View full text Add to dashboard Cite

Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are increasingly being used as preventive treatments for migraine. Their effectiveness and safety were established through numerous randomized placebo-controlled trials and real-world studies, yet a significant proportion of patients do not respond to this treatment, and currently, there is a lack of accepted predictors of response to guide expectations, as data from studies so far are lacking and inconsistent. We searched Embase and MEDLINE databases for studies reporting on predictors of response to CGRP and/or CGRP-receptor (CGRP-R) mAbs, defined as a 30% or 50% reduction in monthly headache or migraine days at varying durations of follow-up. Quantitative synthesis was performed where applicable. We found 38 real-world studies that investigated the association between various predictors and response rates. Based on these studies, good response to triptans and unilateral pain with or without unilateral autonomic symptoms are predictors of a good response to CGRP(-R) mAbs. Conversely, obesity, interictal allodynia, the presence of daily headaches, a higher number of non-successful previous prophylactic medications, and psychiatric comorbidities including depression are predictive of a poor response to CGRP(-R) mAbs. Future studies should confirm these results and help to generate more tailored treatment strategies in patients with migraine.

show abstract